Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
Experienced Healthcare Executive to Lead Finance Organization
“We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion’s CEO. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as a healthcare investment banker, make him an ideal addition to Aurion.”
“I’m thrilled to join Aurion as CFO,” said Don Munoz. “I believe that Aurion’s lead product candidate, AURN001, has significant potential to treat corneal endothelial disease, which can lead to blindness. I look forward to working with the Aurion team to pursue bringing this cell therapy to patients in need.”
Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker. Prior to joining Aurion, Don spent more than nine years as chief financial officer of NuCana plc (NASDAQ: NCNA) (NuCana), a publicly traded biotechnology company developing oncology therapeutics. At NuCana, Don oversaw financial management, investor relations, Securities and Exchange Commission reporting, audit, tax and financial planning and analysis. Don also led NuCana’s
Don’s appointment follows Aurion’s announcement of positive six-month top-line data from its CLARA Phase 1/2 clinical trial in
About Aurion Biotech, Inc.
Aurion’s mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech in 2022. Aurion is advancing AURN001, an investigational, single-administration, allogeneic cell therapy to treat corneal edema secondary to corneal endothelial dysfunction. Aurion developed and has launched the first commercially available corneal endothelial cell therapy in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210293269/en/
Media Contacts:
Judith McGarry
(Corporate Communications)
415-971-2900
judith.mcgarry@aurionbiotech.com
Michele Gray
(Ophthalmology Media)
917-449-9250
michele@mgraycommunications.com
Beth Keshishian
(Biotech & Business Media)
917-912-7195
beth@bethkeshishian.com
Source: Aurion Biotech, Inc.